Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2010

Open Access 01-12-2010 | Research

Mapping onto Eq-5 D for patients in poor health

Authors: Matthijs M Versteegh, Donna Rowen, John E Brazier, Elly A Stolk

Published in: Health and Quality of Life Outcomes | Issue 1/2010

Login to get access

Abstract

Background

An increasing amount of studies report mapping algorithms which predict EQ-5 D utility values using disease specific non-preference-based measures. Yet many mapping algorithms have been found to systematically overpredict EQ-5 D utility values for patients in poor health. Currently there are no guidelines on how to deal with this problem. This paper is concerned with the question of why overestimation of EQ-5 D utility values occurs for patients in poor health, and explores possible solutions.

Method

Three existing datasets are used to estimate mapping algorithms and assess existing mapping algorithms from the literature mapping the cancer-specific EORTC-QLQ C-30 and the arthritis-specific Health Assessment Questionnaire (HAQ) onto the EQ-5 D. Separate mapping algorithms are estimated for poor health states. Poor health states are defined using a cut-off point for QLQ-C30 and HAQ, which is determined using association with EQ-5 D values.

Results

All mapping algorithms suffer from overprediction of utility values for patients in poor health. The large decrement of reporting 'extreme problems' in the EQ-5 D tariff, few observations with the most severe level in any EQ-5 D dimension and many observations at the least severe level in any EQ-5 D dimension led to a bimodal distribution of EQ-5 D index values, which is related to the overprediction of utility values for patients in poor health. Separate algorithms are here proposed to predict utility values for patients in poor health, where these are selected using cut-off points for HAQ-DI (> 2.0) and QLQ C-30 (< 45 average of QLQ C-30 functioning scales). The QLQ-C30 separate algorithm performed better than existing mapping algorithms for predicting utility values for patients in poor health, but still did not accurately predict mean utility values. A HAQ separate algorithm could not be estimated due to data restrictions.

Conclusion

Mapping algorithms overpredict utility values for patients in poor health but are used in cost-effectiveness analyses nonetheless. Guidelines can be developed on when the use of a mapping algorithms is inappropriate, for instance through the identification of cut-off points. Cut-off points on a disease specific questionnaire can be identified through association with the causes of overprediction. The cut-off points found in this study represent severely impaired health. Specifying a separate mapping algorithm to predict utility values for individuals in poor health greatly reduces overprediction, but does not fully solve the problem.
Appendix
Available only for authorised users
Literature
1.
go back to reference NICE: Guide to the methods of technology appraisal. London: NHS. National Institute for Health and Clinical Excellence; 2008. NICE: Guide to the methods of technology appraisal. London: NHS. National Institute for Health and Clinical Excellence; 2008.
2.
go back to reference Brazier JE, Yang Y, Tsuchiya A, Rowen DL: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010, 11: 215–225. 2009 Jul 8 10.1007/s10198-009-0168-zPubMedCrossRef Brazier JE, Yang Y, Tsuchiya A, Rowen DL: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010, 11: 215–225. 2009 Jul 8 10.1007/s10198-009-0168-zPubMedCrossRef
3.
go back to reference Rowen D, Brazier J, Roberts J: Mapping SF-36 onto the EQ-5 D index: How reliable is the relationship? Health Qual Life Outcomes 2009, 7: 27. 10.1186/1477-7525-7-27PubMedCentralPubMedCrossRef Rowen D, Brazier J, Roberts J: Mapping SF-36 onto the EQ-5 D index: How reliable is the relationship? Health Qual Life Outcomes 2009, 7: 27. 10.1186/1477-7525-7-27PubMedCentralPubMedCrossRef
4.
go back to reference Franks PP, Lubetkin E, Gold M, Tancredi D, Jia H: Mapping the SF-12 to the EuroQol EQ-5 D index in a national US sample. Medical decision making 2004,24(3):247–54. 10.1177/0272989X04265477PubMedCrossRef Franks PP, Lubetkin E, Gold M, Tancredi D, Jia H: Mapping the SF-12 to the EuroQol EQ-5 D index in a national US sample. Medical decision making 2004,24(3):247–54. 10.1177/0272989X04265477PubMedCrossRef
5.
go back to reference Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell P, Luengo-Fernandez R: Mapping the modified rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Medical decision making 2010,30(3):341–54. 10.1177/0272989X09349961PubMedCrossRef Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell P, Luengo-Fernandez R: Mapping the modified rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Medical decision making 2010,30(3):341–54. 10.1177/0272989X09349961PubMedCrossRef
6.
go back to reference Ara R, Brazier J: Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5 D preference-based score from published studies (where patient level data are not available). Value in Health 2008, 11: 1131–1143. May 16 10.1111/j.1524-4733.2008.00352.xPubMedCrossRef Ara R, Brazier J: Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5 D preference-based score from published studies (where patient level data are not available). Value in Health 2008, 11: 1131–1143. May 16 10.1111/j.1524-4733.2008.00352.xPubMedCrossRef
7.
go back to reference Benito-Garcia E, Pedro S, Vasconcelos J, Marques RA, Rodrigues A, Chaves I, et al.: Different utility measurement instruments may not disciriminate across disease severity: Results from a cohort of rheumatoid arthritis patients in portugal. ISPOR 12th annual european congress 2009, 24–27. Paris, France, 2009 Benito-Garcia E, Pedro S, Vasconcelos J, Marques RA, Rodrigues A, Chaves I, et al.: Different utility measurement instruments may not disciriminate across disease severity: Results from a cohort of rheumatoid arthritis patients in portugal. ISPOR 12th annual european congress 2009, 24–27. Paris, France, 2009
8.
go back to reference Versteegh M, Leunis A, Luime J, Boggild M, Uyl-De Groot CA, Stolk E: Mapping QLQ-C30, HAQ and MSIS-29 on EQ-5 D. Submitted Versteegh M, Leunis A, Luime J, Boggild M, Uyl-De Groot CA, Stolk E: Mapping QLQ-C30, HAQ and MSIS-29 on EQ-5 D. Submitted
9.
go back to reference Brazier JE, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5 D and SF-6 D across seven patient groups. Health Econ 2004,13(9):873–84. 10.1002/hec.866PubMedCrossRef Brazier JE, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5 D and SF-6 D across seven patient groups. Health Econ 2004,13(9):873–84. 10.1002/hec.866PubMedCrossRef
10.
go back to reference Yang M, Dubois D, Kosinski M, Sun X, Gajria K: Mapping MOS sleep scale scores to SF-6 D utility index. Curr Med Res Opin 2007,23(9):2269–82. 10.1185/030079907X210796PubMedCrossRef Yang M, Dubois D, Kosinski M, Sun X, Gajria K: Mapping MOS sleep scale scores to SF-6 D utility index. Curr Med Res Opin 2007,23(9):2269–82. 10.1185/030079907X210796PubMedCrossRef
11.
go back to reference Geuskens GA, Hazes JMW, Barendregt PJ, Burdorf A: Work and sick leave among patients with early inflammatory joint conditions. Arthritis Rheum 2008,59(10):1458. 10.1002/art.24104PubMedCrossRef Geuskens GA, Hazes JMW, Barendregt PJ, Burdorf A: Work and sick leave among patients with early inflammatory joint conditions. Arthritis Rheum 2008,59(10):1458. 10.1002/art.24104PubMedCrossRef
12.
go back to reference Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003,101(6):2144–51. 10.1182/blood-2002-03-0889PubMedCrossRef Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003,101(6):2144–51. 10.1182/blood-2002-03-0889PubMedCrossRef
13.
go back to reference Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, et al.: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-hodgkin's lymphoma. J Clin Oncol 2003,21(16):3041–50. 10.1200/JCO.2003.01.076PubMedCrossRef Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, et al.: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-hodgkin's lymphoma. J Clin Oncol 2003,21(16):3041–50. 10.1200/JCO.2003.01.076PubMedCrossRef
14.
go back to reference Dolan P: Modeling valuations for the EuroQol health states. Med Care 1997, 35: 1095–108. 10.1097/00005650-199711000-00002PubMedCrossRef Dolan P: Modeling valuations for the EuroQol health states. Med Care 1997, 35: 1095–108. 10.1097/00005650-199711000-00002PubMedCrossRef
15.
go back to reference Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV: The dutch tariff: Results and arguments for an effective design for national EQ-5 D valuation studies. Health Econ 2006,15(10):1121–32. 10.1002/hec.1124PubMedCrossRef Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV: The dutch tariff: Results and arguments for an effective design for national EQ-5 D valuation studies. Health Econ 2006,15(10):1121–32. 10.1002/hec.1124PubMedCrossRef
16.
go back to reference Aaronson NNK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.: The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993,85(5):365–76. 10.1093/jnci/85.5.365PubMedCrossRef Aaronson NNK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.: The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993,85(5):365–76. 10.1093/jnci/85.5.365PubMedCrossRef
17.
go back to reference Bruce B, Fries J: The stanford health assessment questionnaire (HAQ): A review of its history, issues, progress, and documentation. J Rheumatol 2003,30(4):167–78.PubMed Bruce B, Fries J: The stanford health assessment questionnaire (HAQ): A review of its history, issues, progress, and documentation. J Rheumatol 2003,30(4):167–78.PubMed
18.
go back to reference Bruce B, Fries JF: The stanford health assessment questionnaire: Dimensions and practical applications. Health Qual Life Outcomes 2003, 1: 20. 10.1186/1477-7525-1-20PubMedCentralPubMedCrossRef Bruce B, Fries JF: The stanford health assessment questionnaire: Dimensions and practical applications. Health Qual Life Outcomes 2003, 1: 20. 10.1186/1477-7525-1-20PubMedCentralPubMedCrossRef
19.
go back to reference Bansback N, Marra C, Tsuchiya A, Anis A, Guy D, Hammond T, et al.: Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis & Rheumatism 2007,57(6):963–71.CrossRef Bansback N, Marra C, Tsuchiya A, Anis A, Guy D, Hammond T, et al.: Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis & Rheumatism 2007,57(6):963–71.CrossRef
20.
go back to reference McKenzie L, Van der Pol M: Mapping the EORTC QLQ C-30 onto the EQ-5 D instrument: The potential to estimate QALYs without generic preference data. Value in healthlue 2009, 12: 167–71. 10.1111/j.1524-4733.2008.00405.xCrossRef McKenzie L, Van der Pol M: Mapping the EORTC QLQ C-30 onto the EQ-5 D instrument: The potential to estimate QALYs without generic preference data. Value in healthlue 2009, 12: 167–71. 10.1111/j.1524-4733.2008.00405.xCrossRef
21.
go back to reference Marra CA, Esdaile JM, Guh D, Kopec JA, Brazier JE, Koehler BE, et al.: A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004,42(11):1125. 10.1097/00005650-200411000-00012PubMedCrossRef Marra CA, Esdaile JM, Guh D, Kopec JA, Brazier JE, Koehler BE, et al.: A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004,42(11):1125. 10.1097/00005650-200411000-00012PubMedCrossRef
22.
go back to reference Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5 D, SF-6 D, and 15 D instruments. Value in Health 2009, 8: 1151–1157. 10.1111/j.1524-4733.2009.00569.xCrossRef Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5 D, SF-6 D, and 15 D instruments. Value in Health 2009, 8: 1151–1157. 10.1111/j.1524-4733.2009.00569.xCrossRef
23.
go back to reference King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of life research 1996,5(6):555–67. 10.1007/BF00439229PubMedCrossRef King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of life research 1996,5(6):555–67. 10.1007/BF00439229PubMedCrossRef
24.
go back to reference Crott R, Briggs A: Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5 D patient preferences. The European journal of health economics 2010,11(4):427–34. 10.1007/s10198-010-0233-7PubMedCrossRef Crott R, Briggs A: Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5 D patient preferences. The European journal of health economics 2010,11(4):427–34. 10.1007/s10198-010-0233-7PubMedCrossRef
Metadata
Title
Mapping onto Eq-5 D for patients in poor health
Authors
Matthijs M Versteegh
Donna Rowen
John E Brazier
Elly A Stolk
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2010
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-8-141

Other articles of this Issue 1/2010

Health and Quality of Life Outcomes 1/2010 Go to the issue